Table 1 type 2 diabetes characteristic at inclusion

Follow-up (years), mean ± (sd)

4.8 (0.7)

4.4 (1.3)

< 0.001

Age (years), mean ± (sd)

65.2 (12.1)

72.0 (11.5)

< 0.001

Male, %

48.2

55.7

< 0.001

4-year database and LTD history, %

 Diabetic eye complications

1.9

7.3

< 0.001

 Diabetic neuropathy

1.4

8.6

< 0.001

 Severe hypoglycaemia

0.6

2.7

< 0.001

 Keto-lactate acidosis

0.5

2.1

< 0.001

 Lower limb amputations

0.1

1.0

< 0.001

 Myocardial Infarction

-

11.0

 Stroke

-

17.5

 Heart failure

-

16.8

 Peripheral arterial disease

-

14.4

 Chronic kidney disease

22.7

 Cardio-vascular and renal disease

-

4.8

 Chronic obstructive pulmonary disease

1.2

6.1

< 0.001

 Major Bleeding

0.6

4.5

< 0.001

Within 3 months before the index date

 Last antidiabetic treatment dispensing, %

< 0.001

  None

13.3

13.1

  Monotherapy

42.5

39.1

  Bitherapy

22.2

18.4

  Tritherapy or more

11.5

8.6

  Insulin

10.4

20.8

 Last antidiabetic drug dispensing, %

  Metformin

52.9

45.7

< 0.001

  Sulfonylurea

29.1

26.1

< 0.001

  DPP-4 inhibitors

11.7

11.2

< 0.001

  Ascarbose

3.2

2.9

< 0.001

  Metiglinides

5.8

9.0

< 0.001

  GLP1-RA

3.0

3.7

< 0.001

  Insulin

10.4

20.8

< 0.001

 Cardiovascular drug dispensing, %

  Low dose aspirin

22.2

41.2

< 0.001

  Statins

40.1

55.5

< 0.001

  Antihypertensives

5.1

8.5

< 0.001

  ACEI or ARB

53.7

68.9

< 0.001

  Beta blockers

23.8

46.9

< 0.001

  Calcium channel blocker

17.5

30.1

< 0.001

  Low ceiling diuretics

1.1

1.9

< 0.001

  P2Y₁₂ antagonists, %

3.3

20.0

< 0.001